GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, a ...

Bidders for Sanofi’s consumer healthcare unit are revising their offers in part to address concerns around potential ...

Italian pharma group Recordati said on Friday it would buy from Sanofi the global rights to a drug used to treat cold ...

The deal includes additional commercial milestone payments of up to $250 million and will be completed by year-end, subject ...

GSK, Sanofi and CSL Ltd have secured $72 million from the U.S. government to ramp up production of bird flu vaccines, ...

The U.S. government has granted $72 million to European pharma giants GSK Plc (NYSE:GSK), Sanofi SA (NASDAQ:SNY) and ...

Having already been on a winding journey, Enjaymo, which Sanofi acquired through a 2018 buyout of Bioverativ, is now headed ...

Sanofi (SNY), and CSL (CSLLY) win $72M U.S. contract to expand bird flu vaccine production amid fears of human transmission.

CSL Seqirus, Sanofi and GSK have collectively secured $72 million in funding from the U.S. health department to boost the ...

Under the deal announced Friday, the Italian pharma will make an upfront payment of $825 million to Sanofi for global rights ...

Recordati will acquire global rights to Enjaymo from Sanofi for $825M, boosting its rare disease portfolio. The deal includes ...

As Sanofi continues to clean out its medicine chest, Italy’s Recordati is getting in on the action. | Recordati is floating ...